Oncolytics Biotech has entered into a commercial supply agreement with SAFC, a division of Sigma-Aldrich Corp., for the commercial manufacture of Oncolytics’ reovirus, Reolysin. SAFC will perform process validation, continue to supply clinical requirements, and will supply commercial material upon approval. “As a leading global provider of high-quality and reliable biologics manufacturing services we are eager to work with companies focused on bringing novel products to market,” said Gilles C...